Freya Biosciences

About Freya Biosciences

Freya Biosciences is a clinical-stage biotechnology company operating with a transatlantic presence in Copenhagen, Denmark, and Boston, Massachusetts. Founded in 2020 through a collaboration of experts in women's health and reproductive immunology, the company focuses on developing microbial immunotherapies. The business model is centered on pharmaceutical research and development, aiming to create and commercialize novel treatments. Its revenue generation will likely depend on the successful commercialization of its drug candidates through partnerships, licensing deals, or direct sales upon regulatory approval.

The company's primary mission is to address chronic inflammation associated with a range of reproductive system diseases by targeting the vaginal microbiome. Freya's client base consists of women experiencing infertility and other reproductive health issues, particularly those undergoing in vitro fertilization (IVF). The company's scientific approach involves in-depth sequencing of the microbiota from fertile and non-fertile women to gain a detailed understanding of their health status and study numerous immune biomarkers. This data-driven strategy fuels its DYSCOVER™ platform, which identifies specific *Lactobacillus* strains capable of displacing dysbiotic microbiomes and reducing key inflammation biomarkers.

Freya's lead candidate, FB101, is an investigational microbial immunotherapeutic derived from healthy donors, designed to rebalance the vaginal microbiota. Clinical trials have shown that FB101 can resolve dysbiosis and that the administered *Lactobacillus* strains engraft and remain for extended periods. Following positive Phase 1 results, the company is advancing the clinical development of FB101 to improve pregnancy success in women undergoing IVF. Beyond infertility, the company is leveraging its platform to develop treatments for bacterial vaginosis (BV) to prevent pre-term births, an initiative supported by a significant strategic investment from the Bill & Melinda Gates Foundation.

The company was co-founded by CEO Colleen Acosta, a former epidemiologist who applies her experience in communicating complex science to leading the biotech startup. Other co-founders include Johan van Hylckama Vlieg (CSO), Ulrich Binné (CBO), Peter Bisgaard, Laura Ensign, Randi Rich, Anne Bloch Thomsen, and Thomas Rasmussen. Freya has secured substantial funding, including a notable $38 million Series A round in December 2023 and a subsequent $11.8 million investment in November 2024, extending the Series A to approximately $50 million. These funds are dedicated to advancing clinical studies, developing its data science platform, and expanding its research into other conditions like endometriosis-related infertility.